Looking forward, analysts on average predict that earnings for the current quarter would come in between $0.52 and $0.58. Abbott Laboratories makes up approx 1.26% of Moreno Evelyn V’s portfolio. Woodley Farra Manion Portfolio Management Inc. now owns 7,375 shares of the healthcare product maker’s stock valued at $308,000 after buying an additional 100 shares during the last quarter. Trust Co. of Vermont raised its position in shares of Abbott Laboratories by 2.7% in the fourth quarter. The stock established a positive trend of 2.85% in last week and indicated rise of 12.96% in previous month. The shares closed last trade at $41.97, implying that analysts see shares rising about 11.03 per cent in 12 months’ time. Gratus Capital LLC now owns 132,497 shares of the healthcare product maker’s stock valued at $5,950,000 after buying an additional 18,812 shares during the last quarter.
Advertisement
Abbott Laboratories (ABT) has witnessed a rise of 15.5% or 8,163,168 shares in its short figure. They now own 1.02 billion shares or 1.30% more from 1.00 billion shares in 2015Q4. The days to cover are 6 given that the daily volume averaged 10,441,003 shares. ABT stock’s 52-week range is $36.00 – $51.74. The stock’s price moved above its 200 day moving average of $39.98. The company has a market cap of $61.33 billion.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on April 20, 2016. For the reporting quarter, analysts expect the company to deliver $0.53 in earnings per share (EPS). 14 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. NA purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $1,094,000.
Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -5.38 down so far this year. The company’s revenue was down -.2 % compared to the same quarter previous year.
The business also recently declared a quarterly dividend, which will be paid on Monday, August 15th. This represents a $1.04 annualized dividend and a yield of 2.45%. The ex-dividend date of this dividend is Wednesday, July 13th.
Several brokerages recently commented on ABT. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a report on Tuesday, July 5th. The stock has received “BUY” rating after consensus analysis from analysts. The firm owned 2,031,276 shares of the healthcare product maker’s stock after buying an additional 167,776 shares during the period.
Advertisement
04/11/2016 – Abbott Laboratories had its “outperform” rating reiterated by analysts at RBC Capital. In a Bloomberg survey of 22 brokerage companies on July 13, ~68% of these analysts rated Abbott Laboratories as a “buy” and 32% rated it as a “hold”. The fund owned 736,881 shares of the healthcare product maker’s stock after selling 15,212 shares during the period. The company’s target price is 46.6. Its Executive Vice President ALLEN HUBERT L sold 3,400 company shares for $126000.28, in a transaction on 2016-06-28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
